<DOC>
	<DOCNO>NCT00576576</DOCNO>
	<brief_summary>The purpose study evaluate effect Atorvastatin coronary atherosclerosis plaque morphology .</brief_summary>
	<brief_title>Evaluation Atorvastatin Atherosclerosis Composition</brief_title>
	<detailed_description>The primary goal project evaluate effect cholesterol lower drug Atorvastatin composition character coronary atherosclerosis ( heart blockages ) . Atorvastatin known reduce cholesterol , reduce cardiac event , halt progression coronary atherosclerosis . However , reduction cardiac event proportion reduction total amount atherosclerosis . Thus , drug likely decrease cardiac event change composition coronary atherosclerotic plaque . It likely drug cause `` heart blockage '' change `` vulnerable plaque '' `` stable '' plaque . There several feature `` vulnerable plaque '' detect artery heart use intravascular ultrasound . The goal project examine effect atorvastatin atherosclerosis plaque composition use intravascular ultrasound patient undergo serial cardiac catheterization . Our hypothesis atorvastatin reduce number `` vulnerable plaque '' increase number `` stable plaque '' see intravascular ultrasound . We plan enroll total 20 patient . The patient evaluate cardiac catheterization intravascular ultrasound analysis treat atorvastatin 6 month . These 20 patient return cardiac catheterization laboratory 6 month later repeat catheterization intravascular ultrasound evaluation . The secondary goal proposal evaluate human relationship coronary atherosclerosis ( plaque buildup artery heart ) wall shear stress ( force generate wall artery flow blood ) . The reason sub-study great interest understand characteristic cause progression coronary atherosclerosis . Local force shear stress may play important role focal progression `` vulnerable '' atherosclerotic plaque . Indeed , low shear stress know important factor early formation atherosclerosis . However , relationship low shear stress development progression advance `` rupture prone '' ( `` vulnerable '' ) plaque elucidate . Our hypothesis : ( 1 ) `` Vulnerable plaque '' commonly locate area low shear stress ( 2 ) `` Vulnerable plaque '' area low shear stress likely progress follow 6 month plaques locate normal shear stress region .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>1 . The patient eligible undergoing catheterization stable angina acute coronary syndrome 2 . At time catheterization patient `` moderate coronary '' lesion proximal 60mm epicardial coronary artery 3 . `` Moderate lesion '' define lesion deem significant enough warrant evaluation use coronary flow reserve ( CFR ) fractional flow reserve ( FFR ) treat physician 4 . Patient must decision make capacity consent prior catheterization 5 . Ages : All age 6 . Performance Status : level 1 . Screening 1 . Patients coronary bypass graft 2 . Severe valvular heart disease 3 . Patients present ST segment elevation myocardial infarction ( STEMI ) 4 . Inability provide inform consent prior randomization 5 . Creatinine &gt; 1.5 6 . Patients statin LDL &lt; 130 . 7 . Any patient maximum dose statin ( atorvastatin 80mg , simvastatin 80mg , rosuvastatin 20mg , pravastatin 80mg , fluvastatin 80mg ) 8 . Uncontrolled diabetes require intensification therapy 9 . Uncontrolled hypertension require addition angiotensinconverting enzyme inhibitor angiotensin receptor blocker 2 . Angiographic Ineligibility Criteria : 1 . A Left Main lesion great 50 % stenosis 2 . The moderate lesion locate beyond 60mm 3 . Collaterals 4 . Coronary Anatomy require coronary artery bypass grafting ( CABG )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Atherosclerosis , vulnerable plaque , IVUS , shear stress</keyword>
</DOC>